<DOC>
	<DOCNO>NCT01572103</DOCNO>
	<brief_summary>Background : In patient chronic HCV-related liver damage , coffee associate reduced risk progression hepatocellular carcinoma ( HCC ) development . Aim : This prospective trial aim assess mechanism underlie protective effect coffee evolution cirrhosis HCC . Trial design/methods : Forty patient HCV-related hepatitis recruit randomize two group : first consume 4 coffee cups/day/1 month , second remain coffee `` abstinent '' . At day 30 , two group switch exposed coffee second month . Before enter study ( time 0 ) , coffee exposure abstinence evaluate follow parameter : liver function test , viral load , 8-hydroxydeoxyguanosine ( marker oxidative DNA damage ) , telomere length , apoptosis collagen deposition .</brief_summary>
	<brief_title>Coffee Effect HCV-related Hepatitis</brief_title>
	<detailed_description>Patients Forty patient HCV-related chronic liver disease refer Gastroenterology Unit Padua out-patient clinic prospectively recruit enter study . In patient presence anti-HCV antibody assay third-generation immunoenzymatic test ( Ortho Diagnostic Systems , Raritan , NJ ) confirmatory test ( recombinant immunoblotting assay , Chiron Corp. , Emeryville , CA ) . A standardized genotyping assay ( Inno-Lipa HCV III , Innogenetics , Gent , Belgium ) use . Only patient fulfill follow inclusion criterion recruit : - HCV-related chronic hepatitis cirrhosis , bioptic ( within previous 24 month ) confirmation clinical diagnosis case cirrhosis ; ( Prothrombin Time - PT , White Blood Cells - WBC platelets - PLT , Ultra Sound - US examination ) ; - anti-HCV HCV-RNA positivity Aspartate aminotransferase ( AST ) /Alanine aminotransferase ( ALT ) least 1.5x ; - age range 30-80 year ; - ongoing interferon treatment , previous treatment response relapse accept . The study approve Hospital Ethical Committee ( Prot . 1755 P , Azienda Ospedaliera di Padova ) , patient ' participation voluntary patient sign inform consent participation , information note deliver patient 's attend general practitioner . Before begin intervention phase , patient , demographical data collect , together information coffee smoking habit , alcohol , fruit , vegetable , anti-inflammatory drug consumption , energy nutrient intake , potential bias . All data assess use quantity-frequency questionnaire design use present study . At time 0 ( T0 ) patient categorize two group relation routine coffee intake : 0-2 cups/day 3-5 cups/day . This cut-off chosen paper effect coffee consumption observe 2 cups/day . Subjects ask maintain , throughout study , alimentary voluptuary habit , use caffeine-containing beverage forbid . Trial design study Patients investigate marker begin study ( T0 ) randomize use computer-generated list ( StatsDirect statistic program ) two group , either 4 coffee cups/day intake 1 month abstinence time period . Obviously , blind possible decided prescribe wash-out period , T0 sample examined relation patient ' routine coffee consumption . After 30 day , patient re-tested , shift opposite `` treatment '' ( coffee arm abstinent first month vice versa consume coffee ) check second time period . Each patient therefore test three time , T0 , he/she enters study , coffee follow abstinence , patient control two phase . For seek simplicity data obtain follow coffee consumption compare data obtain abstinence , irrespective time sequence exposure/abstinence . Considering ( basis publish data ) expect coffee effect least 40 % exposed subject , 1 control case , 5 % alpha error 80 % power , sample size require ( 20 case 20 control ) correspond select sample study . Additionally , study , give cross design patient investigate twice , coffee exposure abstinence , actual number patient investigate 40 per arm , twice high therefore , require . The patient give form registered deviation compliance respect coffee intake appropriate telephone contact report immediately side effect . To reduce risk bias due inter-individual change preparation coffee , patient provide typical Italian-style coffee machine stove-top type ( MokaTMBialetti ) , required amount coffee preparation 4 coffee cups/day ( 8 g coffee preparation ) instruction prepare . The coffee brand 100 % Coffea arabica product shelf . We also want analyze product use . The analysis perform contract lab ( Eurofins analytic GmbH - Hamburg-Germany ) . The patient instructed drink differently prepared coffee report appropriate form deviation study . Methods Blood sample collect stored −20°C longer 3 week . In study follow parameter evaluate : 1 . AST/ALT , gammaglutamyl-transpeptidase ( γGT ) alkaline phosphatase ( ALP ) level ; 2. viral load ( HCV-RNA titer ) , 3. marker oxidative damage : 8-hydroxydeoxyguanosine ( 8-OHdG ) , nitric oxide ( NO ) , Advanced Oxidation Protein Products ( AOPP ) , 4. marker genomic stability : Telomere Length ( TL ) , 5. marker cell death : M30 M30/M65 , 6. marker liver fibrosis angiogenesis : Procollagen Type III ( PIIINP ) Vascular Endothelial Growth Factor ( VEGF ) . Liver Function Tests determination Serum level AST ALT , gammaGT ALP determine part routine clinical procedure . HCV-RNA determination The presence HCV-RNA serum assess amplification PCR 5 ' untranslated region ( 5'-UTR ) HCV , conserve region virus . The test perform subject positive anti-HCV antibody ( screen test ) . The amplification perform two step , 'nested PCR ' . 8-OHdG determination This assay carry follow : brief , assay consist 3 step : ( ) genomic DNA extraction use Wizard Genomic DNA Purification Kit ( Promega Italia , Milano ) ; ( ii ) nuclease P1 alkaline phosphatase hydrolysis DNA ; ( iii ) 8-OHdG determination use HPLC equip electrochemical detector ( HPLC-ED ) ( ESA Coulochem II 5200 A , Bedford , MA ) . The 8-OHdG level express number 8-OHdG adduct/105 dG . NO determination Serum NO level spectrophotometrically assay measure accumulation stable degradation product , nitrate nitrite ( Oxford Biomedical Research , USA ) . NO level express µmol/L , marker nitric oxide synthase activation nitrosation . AOPP determination Plasma AOPP level measure spectrophotometric method perform Witko-Sarsat . AOPP concentration express µmol/L chloramines-T equivalent . TL analysis quantitative PCR Genomic DNA extract use also measure TL use method develop Cawthon . Two 96-well plate prepared experiment , one containing telomere primer 36B4 , encode acidic ribosomal phosphoprotein P0 use single copy gene . Each 25 µl PCR reaction include 40 ng DNA , SYBR Green Master Mix ( Applied Biosystems , Foster City , CA ) primers final concentration 270 nM Tel-1 900 nM Tel-2 300 nM 36B4u 500 nM 36B4d respectively . PCR amplification perform ABI PRISM 7900 ( Applied Biosystem ) . In plate , standard curve produce range 4 80 ng human reference DNA ( Applied Biosystem ) . The thermal cycling profile telomere amplification 95°C 10 min , follow 30 cycle 95°C 5 , 56°C 10 72°C 60 30 cycle 95°C 5 , 58°C 10 72°C 40 s. Following amplification , dissociation curve perform order confirm specificity reaction . All sample assay triplicate test reproducibility assay assay negative control evaluate . Fluorescence signal dissociation curve analyze ABI 7900 SDS 2.3 software . Cell death determination The M30-Apoptosense ELISA ( Peviva , USA ) one step vitro immunoassay quantitative determination apoptosis-associated CK18Asp396 ( M30 ) neo-epitope plasma . The concentration antigen quantifies ongoing apoptotic cell death , express U/L . The M30-Apoptosense ELISA use combination M65 ELISA ( Peviva , USA ) , quantitative determination total soluble CK18 release dead cell ( necrotic apoptotic ) . The concentration antigen express U/L . PIIINP VEGF determination Plasma PIIINP level determine use ELISA kit ( USCN , China ) . PIIINP level express ng/mL marker tissue collagen deposition fibrosis . Serum VEGF determine marker neo-angiogenesis tissue re-modeling use ELISA kit ( Bender MedSystems , Austria ) , data express ng/L . Statistic Data analyze use one-way ANOVA , pair t-test , Student 's t-test unpaired data , linear regression ( SPSS , STATSDIRECT ) statistical significance set p &lt; 0.05 ( 2-tailed ) . All comparison regard coffee exposure abstinence carry within patient within group , use , say , pair data approach .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<criteria>HCVrelated chronic hepatitis cirrhosis , bioptic ( within previous 24 month ) confirmation clinical diagnosis case cirrhosis ( Prothrombin Time PT , White Blood Cells WBC platelet PLT , Ultra Sound US examination suggestive cirrhosis ) ; antiHCV HCVRNA positivity AST/ALT least 1.5x ; age range 3080 year ; ongoing interferon treatment , previous treatment response relapse accept . ongoing interferon treatment history relevant cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>